CD4 and neoplasm: Deficiency in CCR7 within the cDC1 subset hinders anti-tumor T cell response, fostering tumor growth.386 Additionally, tumor-derived ligands binding to the liver X receptor (LXR) have been found to hinder the migration of DCs to TDLNs.387 Recent findings indicate that the CCR7-dependent migration of cDC2 from the TME to TDLNs is crucial for triggering the anti-tumor activity of CD4+ T cells.